Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias.
Grogan J, Gerona R, Snow JW, Kao L.
J Emerg Med · journal article; case reports · DOI 10.1016/j.jemermed.2019.06.052 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ibogaine. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
13 träffarBiosynthesis of an Anti-Addiction Agent from the Iboga Plant.
Farrow SC, Kamileen MO, Caputi L, Bussey K, Mundy JEA, McAtee RC, Stephenson CRJ, O'Connor SE.
J Am Chem Soc · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; rapid-communication; journal article · DOI 10.1021/jacs.9b05999Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
Brown TK, Noller GE, Denenberg JO.
J Psychoactive Drugs · multicenter study; journal article; observational study · DOI 10.1080/02791072.2019.1598603Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.
Marton S, González B, Rodríguez-Bottero S, Miquel E, Martínez-Palma L, Pazos M, Prieto JP, Rodríguez P, Sames D, Seoane G, Scorza C, Cassina P, Carrera I.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2019.00193Morphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor Ligands.
Floresta G, Dichiara M, Gentile D, Prezzavento O, Marrazzo A, Rescifina A, Amata E.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms20030488A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T.
Prog Brain Res · research support, non-u.s. gov't; journal article · DOI 10.1016/bs.pbr.2018.08.002Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
Corkery JM.
Prog Brain Res · review; journal article · DOI 10.1016/bs.pbr.2018.08.005DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko MJ, Witt-Enderby PA, Surratt CK.
ACS Chem Neurosci · historical article; review; journal article · DOI 10.1021/acschemneuro.8b00294Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.
Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V.
Hum Exp Toxicol · review; journal article · DOI 10.1177/0960327107087802Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.
Jacobs MT, Zhang YW, Campbell SD, Rudnick G.
J Biol Chem · journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m704456200Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors.
Layer RT, Skolnick P, Bertha CM, Bandarage UK, Kuehne ME, Popik P.
Eur J Pharmacol · journal article · DOI 10.1016/0014-2999(96)00304-4Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.
Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL.
Life Sci · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1016/0024-3205(95)00273-9The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.
Popik P, Layer RT, Skolnick P.
Psychopharmacology (Berl) · journal article · DOI 10.1007/bf02245000